Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial

被引：0
|
作者：
Mease, Philip [1 ,2 ]
Helliwell, Philip S. [3 ]
Silwinska-Stanczyk, Paula [4 ]
Miakisz, Malgorzata [5 ]
Ostor, Andrew [6 ]
Peeva, Elena [7 ]
Vincent, Michael [7 ]
Sikirica, Vanja [8 ]
Winnette, Randall [9 ]
Qiu, Ruolun
Li, Gang [8 ]
Feng, Gang [7 ]
Beebe, Jean [7 ]
Martin, David [7 ]
机构：
[1] Swedish Med Ctr Providence St Joseph Hlth, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[4] REUMATIKA Centrum Reumatol NZOZ, Warsaw, Poland
[5] Twoja Przychodnia Centrum Medyczne Nowa Sol, Nowa Sol, Poland
[6] Monash Univ, Cabrini Hosp & Emeritus Res, Melbourne, Australia
[7] Pfizer Inc, Cambridge, MA USA
[8] Pfizer Inc, Collegeville, PA USA
[9] Pfizer Inc, New York, NY USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0488
引用
收藏
页码：1009 / 1011
页数：3
相关论文
共 50 条
  • [1] Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
    Mease, Philip
    Helliwell, Philip
    Silwinska-Stanczyk, Paula
    Miakisz, Malgorzata
    Ostor, Andrew
    Peeva, Elena
    Vincent, Michael S.
    Sun, Qiankun
    Sikirica, Vanja
    Winnette, Randall
    Qiu, Ruolun
    Li, Gang
    Feng, Gang
    Beebe, Jean S.
    Martin, David A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 (08) : 1370 - 1380
  • [2] Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
    Mease, Philip
    Coates, Laura C.
    Helliwell, Philip S.
    Stanislavchuk, Mykola
    Rychlewska-Hanczewska, Anna
    Dudek, Anna
    Abi-Saab, Walid
    Tasset, Chantal
    Meuleners, Luc
    Harrison, Pille
    Besuyen, Robin
    Van der Aa, Annegret
    Mozaffarian, Neelufar
    Greer, Joy M.
    Kunder, Rebecca
    Van den Bosch, Filip
    Gladman, Dafna D.
    [J]. LANCET, 2018, 392 (10162): : 2367 - 2377
  • [3] EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)
    Helliwell, P.
    Van den Bosch, F.
    Coates, L. C.
    Gladman, D. D.
    Tasset, C.
    Meuleners, L.
    Gilles, L.
    Gheyle, L.
    Trivedi, M.
    Alani, M.
    Besuyen, R.
    Mease, P. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 761 - 762
  • [4] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Mease, P. J.
    Deodhar, A.
    Van der Heijde, D.
    Behrens, F.
    Kivitz, A.
    Kim, J.
    Singhal, S.
    Nowak, M.
    Banerjee, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 314 - 315
  • [5] Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
    Mease, Philip J.
    Deodhar, Atul
    van der Heijde, Desiree
    Behrens, Frank
    Kivitz, Alan
    Neal, Jeffrey
    Nys, Marleen
    Lehman, Tom
    Delev, Nikolay
    Korish, Shimon
    Nowak, Miroslawa
    Banerjee, Subhashis
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3167 - 3168
  • [6] Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
    Kivitz, Alan
    Muensterman, Elena Tomaselli
    Kavanaugh, Arthur
    van der Heijde, Desiree
    Klimiuk, Piotr A.
    Valenzuela, Guillermo
    Dokoupilova, Eva
    Poirier, Gabrielle
    Srivastava, Bhaskar
    Dasen, Sue
    Zhang, Xinyan
    Trivedi, Mona
    Weng, Haoling Holly
    Hong, Ting
    Pothula, Peter
    Baraliakos, Xenofon
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 5216 - 5219
  • [7] Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
    King, Brett
    Ko, Justin
    Forman, Seth
    Ohyama, Manabu
    Mesinkovska, Natasha
    Yu, Guanglei
    McCollam, Jill
    Gamalo, Margaret
    Janes, Jonathan
    Edson-Heredia, Emily
    Holzwarth, Katrin
    Dutronc, Yves
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (04) : 847 - 853
  • [8] SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIAL
    Mease, P. J.
    Deodhar, A.
    Van der Heijde, D.
    Behrens, F.
    Kivitz, A.
    Neal, J.
    Nys, M.
    Lehman, T.
    Delev, N.
    Korish, S.
    Nowak, M.
    Banerjee, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 842 - 843
  • [9] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
    Papp, K. A.
    Menter, A.
    Strober, B.
    Langley, R. G.
    Buonanno, M.
    Wolk, R.
    Gupta, P.
    Krishnaswami, S.
    Tan, H.
    Harness, J. A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) : 668 - 677
  • [10] EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Mease, P. J.
    Deodhar, A.
    Van der Heijde, D.
    Behrens, F.
    Kivitz, A.
    Lehman, T.
    Wei, L.
    Nys, M.
    Banerjee, S.
    Nowak, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 137 - 138
12345